CFGS
MDGL icon

Concourse Financial Group Securities’s Madrigal Pharmaceuticals MDGL Stock Holding History

Concourse Financial Group Securities’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$324 – 1260
2024
Q4 		$324 Hold
1
– – ﹤0.01% 2175
2024
Q3 		$212 Hold
1
– – ﹤0.01% 2188
2024
Q2 		$280 Hold
1
– – ﹤0.01% 2241
2024
Q1 		$267 Hold
1
– – ﹤0.01% 2256
2023
Q4 		$231 Buy
+1
New +$175 ﹤0.01% 2233

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Concourse Financial Group Securities's MDGL Position: Q1 2025 in Review

Concourse Financial Group Securities sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2025, closing a stake of 1 share — an estimated $324 sold.

Concourse Financial Group Securities first reported a position in MDGL in Q4 2023 and held it in 5 quarters. The position peaked at $324 in Q4 2024. 321 funds tracked by Wall St. Rank hold MDGL as of Q1 2025.

  • Concourse Financial Group Securities reported no remaining Madrigal Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Concourse Financial Group Securities sold 1 Madrigal Pharmaceuticals share in Q1 2025, an estimated $324.
  • Concourse Financial Group Securities first reported a position in Madrigal Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Concourse Financial Group Securities's Madrigal Pharmaceuticals position peaked at $324 in Q4 2024.
  • 321 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2025.

Based on Concourse Financial Group Securities's 13F filing for Q1 2025.